Pacira to Sell iovera Business to Zimmer Biomet for Up to $140 Million
Pacira BioSciences is divesting its iovera business to bolster its balance sheet and focus on biopharmaceuticals. The strategic M&A deal provides immediate cash flow to pay down debt while streamlining operations for growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day